BullFrog AI Fails Nasdaq Equity Requirement Extension, Faces Delisting
summarizeSummary
BullFrog AI Holdings, Inc. has failed to meet the terms of its Nasdaq extension for the minimum stockholders' equity requirement, putting its listing at severe risk. This follows an initial notice in August 2025 and an extension granted until February 2026. While the company intends to request a hearing, there is no guarantee of a further extension or successful compliance. Delisting would significantly impair the company's ability to raise capital and could lead to a material decline in stock price, posing a critical threat to its operational viability.
check_boxKey Events
-
Failed to Meet Nasdaq Extension Terms
The company received notice from Nasdaq on February 19, 2026, that it had not met the terms of the extension granted to comply with the minimum $2,500,000 stockholders' equity requirement.
-
Subject to Delisting
As a result of failing the extension terms, the company's securities are now subject to delisting from The Nasdaq Capital Market.
-
Intends to Request Hearing
BullFrog AI plans to timely request a hearing before an independent Nasdaq Hearings Panel, which will automatically stay any suspension or delisting action pending the hearing.
-
Significant Risk of Delisting
There is no assurance that the Panel will grant additional time or that the company will ultimately regain compliance, with delisting posing severe risks to liquidity and capital raising.
auto_awesomeAnalysis
BullFrog AI Holdings, Inc. has failed to meet the terms of its Nasdaq extension for the minimum stockholders' equity requirement, putting its listing at severe risk. This follows an initial notice in August 2025 and an extension granted until February 2026. While the company intends to request a hearing, there is no guarantee of a further extension or successful compliance. Delisting would significantly impair the company's ability to raise capital and could lead to a material decline in stock price, posing a critical threat to its operational viability.
在该文件披露时,BFRG的交易价格为$0.59,交易所为NASDAQ,所属行业为Life Sciences,市值约为$611.6万。 52周交易区间为$0.43至$3.38。 这份文件被评估为消极市场情绪,重要性评分为9/10。